{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-175567","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.624647+00:00","generated_at":"2026-05-17T17:47:31.239924+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tectonic Therapeutic Q2 net loss $20M; cash $287.4M; TX45 PH-ILD Phase 2 planned 2026","bullets":["Net loss of $20.0M in Q2 2025 vs $12.7M in Q2 2024; R&D expenses rose to $17.2M from $7.1M.","Cash and cash equivalents $287.4M as of June 30, 2025; expected cash runway into Q4 2028.","TX45 Phase 1b Part A results: 19% reduction in PCWP, 18.5% improvement in cardiac output, >30% PVR reduction in CpcPH.","Part B of TX45 Phase 1b in PH-HFrEF enrollment completed; topline results expected early Q4 2025.","New PH-ILD Phase 2 trial for TX45 to start in 2026; TX2100 Phase 1 expected Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-175567","json":"https://secwatch.observer/filing/0001193125-25-175567.json","markdown":"https://secwatch.observer/filing/0001193125-25-175567.md","text":"https://secwatch.observer/filing/0001193125-25-175567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/0001193125-25-175567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/d36621d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:47:31.239924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}